Salmonellosis is globally recognized as one of the leading causes of acute human bacterial gastroenteritis resulting from the consumption of animal-derived products, particularly those derived from the poultry and pig industry. Salmonella spp. is generally associated with self-limiting gastrointestinal symptoms, lasting between 2 and 7 days, which can vary from mild to severe. The bacteria can also spread in the bloodstream, causing sepsis and requiring effective antimicrobial therapy; however, sepsis rarely occurs. Salmonellosis control strategies are based on two fundamental aspects: (a) the reduction of prevalence levels in animals by means of health, biosecurity, or food strategies and (b) protection against infection in humans. At the food chain level, the prevention of salmonellosis requires a comprehensive approach at farm, manufacturing, distribution, and consumer levels. Proper handling of food, avoiding cross-contamination, and thorough cooking can reduce the risk and ensure the safety of food. Efforts to reduce transmission of Salmonella by food and other routes must be implemented using a One Health approach. Therefore, in this review we provide an update on Salmonella, one of the main zoonotic pathogens, emphasizing its relationship with animal and public health. We carry out a review on different topics about Salmonella and salmonellosis, with a special emphasis on epidemiology and public health, microbial behavior along the food chain, predictive microbiology principles, antimicrobial resistance, and control strategies.

This study reports the susceptibility to antimicrobial agents of staphylococci 4 (n=105) isolated from dogs, and the factors associated with this resistance. The study 5 animals were 23 healthy dogs (group A), 24 with first-time pyoderma (group B), and 27 6 with recurrent pyoderma that had undergone long-term antibiotic treatment (group C). 7 Staphylococci were more commonly isolated from the pyoderma-affected than the 8 healthy dogs (p<0.0001). 9 10 Some 78% of the isolates were resistant to at least one antimicrobial agent. 11 Resistance to amoxicillin-clavulanate,cephalosporins (OR 4.29, 95% CI [1.15, 16.3] 12 respectively), enrofloxacin (OR 9.47, 95% CI [1.53, 58.5]) and ciprofloxacin (OR 79.7 13 95% CI [3.26, 1947.4]) was more common among group C isolates. Some 32% of all 14 the isolates were multiresistant (MR) and 10.4% were methicillin-resistant (MRS). The 15 probability of isolating MRS staphylococci in group C increased by a factor of four 16 (95% CI [1.18, 17.9]) compared to A plus B. Multi-resistant (MR) isolates were 17 obtained more commonly from urban than rural dogs (OR 3.79, 95% CI [1.09, 13.17]). 18 All the MRS staphylococci encountered were obtained from urban dogs and more 19 commonly from male dogs (p= 0.07). 20 21 This study shows that dogs bred in urban habitat, with a history of antibiotic 22 therapy in the past year represents significant risk of being carriers of isolates resistant 23 to methicillin (MRS) and other antimicrobials. These factors should be considered 24 before applying an antimicrobial treatment in veterinary clinics

Purified polysaccharide and conjugate vaccines are widely used for preventing infections in adults and in children against the Gram-positive bacterium Streptococcus pneumoniae, a pathogen responsible for high morbidity and mortality rates, especially in developing countries. However, these polysaccharide-based vaccines have some important limitations, such as being serotype-dependent, being subjected to losing efficacy because of serotype replacement and high manufacturing complexity and cost. It is expected that protein-based vaccines will overcome these issues by conferring a broad coverage independent of serotype and lowering production costs. In this study, we have applied the “shaving” proteomic approach, consisting of the LC/MS/MS analysis of peptides generated by protease treatment of live cells, to a collection of 16 pneumococcal clinical isolates from adults, representing the most prevalent strains circulating in Spain during the last years. The set of unique proteins identified in all the isolates, called “pan-surfome”, consisted of 254 proteins, which included most of the protective protein antigens reported so far. In search of new candidates with vaccine potential, we identified 32 that were present in at least 50% of the clinical isolates analyzed. We selected four of them (Spr0012, Spr0328, Spr0561 and SP670_2141), whose protection capacity has not yet been tested, for assaying immunogenicity in human sera. All of them induced the production of IgM antibodies in infected patients, thus indicating that they could enter the pipeline for vaccine studies. The pan-surfomic approach shows its utility in the discovery of new proteins that can elicit protection against infectious microorganisms.